Page 82 - GPD-4-1

Gene & Protein in Disease Sickle cell disease’s journey

C677T, and prothrombin G20210A among Asian Indian 2005;294:81-90.
sickle cell patients. Clin Appl Thromb. 2011;18:320-323.
doi: 10.1001/jama.294.1.81
doi: 10.1177/1076029611425830
28. Green D. Thrombogenesis in sickle cell disease. J Lab Clin
16. Moreira Neto F, Lourenço DM, Noguti MAE, et al. The Med. 1999;134:329-330.
clinical impact of MTHFR polymorphism on the vascular 29. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet.
complications of sickle cell disease. Braz J Med Biol Res. 2004;364:1343-1360.
2006;39:1291-1295.
doi: 10.1016/S0140-6736(04)17192-4
doi: 10.1590/s0100-879x2006001000004
30. Odièvre MH, Verger E, Silva-Pinto AC, Elion J.
17. Horan J, Lerner N. Prediction of adverse outcomes in children Pathophysiological insights in sickle cell disease. Indian J
with sickle cell disease. N Engl J Med. 2000;342:1612-1613.
Med Res. 2011;134:532-537.
doi: 10.1056/NEJM200005253422114
31. Booth C, Inusa B, Obaro SK. Infection in sickle cell disease:
18. Kaul D, Hebbel R. Hypoxia/reoxygenation causes A review. Int J Infect Dis. 2010;14:e2-e12.
inflammatory response in transgenic sickle mice but not in doi: 10.1016/j.ijid.2009.03.010
normal mice. J Clin Investig. 2000;106:411-420.
32. Silva DGH, Junior EB, De Almeida EA, Bonini-
doi: 10.1172/JCI9225 Domingos CR. Oxidative stress in sickle cell disease: An
19. Chiang EY, Frenette PS. Sickle cell vaso-occlusion. Hematol overview of erythrocyte redox metabolism and current
Oncol Clin N Am. 2002;9:771-794, 5. antioxidant therapeutic strategies. Free Radic Biol Med.
2013;65:1101-1109.
doi: 10.1016/j.hoc.2005.08.002
doi: 10.1016/j.freeradbiomed.2013.08.181
20. Frenette PS, Atweh GF. Sickle cell disease: Old discoveries,
new concepts, and future promise. J Clin Investig. 33. Messonnier LA. Mitochondrial function in sickle cell
2007;117:850-858. disease. Blood. 2022;139:1616-1617.
doi: 10.1172/JCI30920 doi: 10.1182/blood.2021015216
21. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial 34. Kurantsin-Mills J, Ofosu FA, Safa TK, Siegel RS, Lessin LS.
biology of sickle cell disease: Inflammation and a chronic Plasma factor VII and thrombin-antithrombin III levels
vasculopathy. Microcirculation. 2004;11:129-151. indicate increased tissue factor activity in sickle cell patients.
Br J Haematol. 1992;81:539-544.
22. Elion JE, Brun M, Odievre MH, Lapoumeroulie CL,
Krishnamoorthy R. Vaso-occlusion in sickle cell anemia: doi: 10.1111/j.1365-2141.1992.tb02989.x
Role of interactions between blood cells and endothelium. 35. Peters M., Plaat BE, Cate HT, Wolters HJ, Weening RS,
Hematol J. 2004;5:S195-S198.
Brandjes DP. Enhanced thrombin generation in children
doi: 10.1038/sj.thj.6200452 with sickle cell disease. Thromb Haemost. 1994;71:169-172.
23. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. 36. Alkindi S, Al-Ghadani AR, Al-Zeheimi SR, et al. Predicting
Circulating activated endothelial cells in sickle cell anemia. risk factors for thromboembolic complications in patients
N Engl J Med. 1997;337:1584-1590. with sickle cell anaemia-lessons learned for prophylaxis.
J Int Med Res. 2021;49:3000605211055385.
doi: 10.1056/NEJM199711273372203
37. Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S,
24. Mack AK, Kato GJ. Sickle cell disease and nitric oxide:
A paradigm shift? Int J Biochem Cell Biol. 2006;38:1237-1243. Machghoul S. Abnormalities of coagulation and fibrinolysis
in homozygous sickle cell disease. Hematol Cell Ther.
doi: 10.1016/j.biocel.2006.01.010 1996;38:279-284.
25. Kato GJ. Defective nitric oxide metabolism in sickle cell doi: 10.1007/s00282-996-0279-2
disease. Pediatr Blood Cancer. 2014;62:373-374.
38. Key NS, Slungaard A, Dandelet L, et al. Whole blood tissue
doi: 10.1002/pbc.25297 factor procoagulant activity is elevated in patients with
sickle cell disease. Blood. 1998;91:4216-4223.
26. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free
hemoglobin limits nitric oxide bioavailability in sickle-cell 39. Westerman MP, Green D, Gilman-Sachs A, et al.
disease. Nat Med. 2002;8:1383-1389. Antiphospholipid antibodies, proteins C and S, and
coagulation changes in sickle cell disease. J Lab Clin Med.
doi: 10.1038/nm1202-799
1999;134:352-362.
27. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated
arginine metabolism, hemolysis-associated pulmonary doi: 10.1016/s0022-2143(99)90149-x
hypertension, and mortality in sickle cell disease. JAMA. 40. Setty BNY, Rao AK, Stuart MJ. Thrombophilia in sickle cell

Volume 4 Issue 1 (2025) 13 doi: 10.36922/gpd.4361